Q-omics provides the consensus-scored SKA1 profile across patient tissues and cancer cell-line models. SKA1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SKA1 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, SKA1 RNA expression shows 27,773 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where SKA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SKA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SKA1 survival associations across molecular data types. SKA1 RNA expression shows survival associations in the most cancer types (29), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SKA1 RNA expression–survival associations across cancer types. High SKA1 expression shows unfavorable associations in ACC, KIRP, MESO, KIRC, KICH and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SKA1 RNA expression.
This table summarizes SKA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SKA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SKA1 shows higher tumor expression in HNSC, BLCA, KIRP, KIRC, LUSC and LUAD. The HNSC box plot shows higher SKA1 RNA expression in tumor versus normal tissue (log2 FC = +1.890, t-test p < 0.001).
This table shows molecular features associated with SKA1 in patient tissues and cancer cell lines. In patient samples, SKA1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SKA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUSC.
